Scientific diligence for emerging technology investments.
Fenway Scientific Group helps venture capital firms, angel investors, and institutional partners evaluate scientific credibility, technical feasibility, and market positioning across emerging biotech and deep-tech opportunities.
A focused engagement model.
Fenway Scientific Group helps venture capital firms, angel investors, and institutional partners evaluate scientific credibility, technical feasibility, and market positioning across emerging biotech and deep-tech opportunities. Every engagement is led by PhD-level specialists, scoped to the question at hand, and delivered in formats designed for executive and investment decision-making.
Core capabilities
Scientific due diligence on biotech startups
Technology validation and technical risk assessment
Competitive landscape and market intelligence analysis
Scientific interpretation for non-technical stakeholders
Translational and commercialization assessment
What the work looks like.
- Reviewing early-stage biotech platforms
- Evaluating therapeutic differentiation
- Assessing scientific and technical risk
- Mapping competitive scientific landscapes
- Translating research complexity into investment insight
Who we work with.
[ C01 ]
Venture capital firms
[ C02 ]
Angel investors
[ C03 ]
Family offices
[ C04 ]
Strategic corporate investors
[ C05 ]
Innovation-focused institutional partners
How the engagement moves.
A measured arc from question to evidence-led recommendation — calibrated to the decision at hand.
Define investment or diligence question
We start by framing the specific decision the diligence must inform — investment hypothesis, technical concern, or comparative question.
Assemble domain specialists
We activate the right combination of PhD-level scientists from the collective based on the underlying technology and research domain.
Review technical materials and literature
Rigorous evaluation of primary literature, raw data, IP, and the competitive scientific landscape — not surface-level summaries.
Deliver structured strategic analysis
Evidence-led memos and briefings formatted for IC review, with clear framing of risk, differentiation, and unresolved questions.